


PHARMACEUTICAL 2018

ENDOCYTE INC Rank 201 of 349





PHARMACEUTICAL 2018

ENDOCYTE INC Rank 201 of 349

The relative strengths and weaknesses of ENDOCYTE INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDOCYTE INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 352% points. The greatest weakness of ENDOCYTE INC is the variable Research and Development, reducing the Economic Capital Ratio by 175% points.

The company's Economic Capital Ratio, given in the ranking table, is -224%, being 54% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	98,573
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,546
Liabilities, Non-Current	0
Other Assets	7.1
Other Compr. Net Income	-23
Other Expenses	0
Other Liabilities	732
Other Net Income	1,112
Property and Equipment	2,182
Research and Development	42,406
Revenues	0
Selling, General and Administrative Expense	13,770

Output Variable	Value in 1000 USD
Assets	100,762
Liabilities	5,278
Expenses	56,176
Stockholders Equity	95,484
Net Income	-55,064
Comprehensive Net Income	-55,076
Economic Capital Ratio	-224%